• Define & Identify Progressive Fibrosis Phenotypes Including & Beyond IPF
  • Navigate Phase 3 Endpoints Across Indications & the ILD Market Potential
  • Explore Systemic Fibrosis for Connective Tissue ILDs: Scleroderma, RA-ILD & Myositis-Related ILD

_________________

June 13-15, 2023 | Boston MA

Welcome to the 3rd ILD Summit

The ILD Summit returns for the third year as the definitive industry-dedicated forum to explore the ILD therapeutic development potential to evaluate IPF pipelines for progressive pulmonary fibrosis and beyond.

There remains huge opportunity to develop the next era of novel treatments for this underserved population to develop personalized therapies for each patient with ILDs, both including and beyond IPF, and to revolutionize therapeutics for these devastating diseases.

Ongoing investment and collaboration continue to flood into the space, with the two approved therapeutics for IPF near to losing their patents and generics. With industry hailing this the time of the ‘lung technology revolution’, there has never been a more exciting time for this space.

The Summit provides the optimal opportunity and touchpoint in 2023 to meet with 100+ industry leaders and key opinion leading academics to:

  • Delve into defining and identifying progressive fibrosis phenotypes
  • Explore phase 3 endpoints across indications
  • Evaluate the ILD market potential
  • Investigate connective tissue ILDs: Scleroderma, rheumatoid arthritis related ILD and myositis related ILD
  • And so much more...

Don’t miss this unique opportunity to hear from and connect with drug developers and researchers supercharging life-changing IPF, ILD and PPF therapies into the clinic and to patients in need.

World-Class Speaker Faculty Includes:

ILD Summit Attending Companies Include:

MicrosoftTeams-image (11)

Our Partners:

Testimonials:

 “The ILD Summit was a high quality event bringing together leaders from academia and industry sharing the latest research and clinical learnings in the field of fibrotic pulmonary disease”

Acceleron

 “A great interactive experience among industry and academic colleagues and potential collaborators, sharing knowledge to advance science and drug discovery for ILDs”

Boehringer Ingelheim

“The meeting provides a very thorough review of the ILD landscape from bench to bedside”

Lassen Therapeutics

Other Events in the Series: